Steel Grove Capital Advisors LLC Acquires 56,033 Shares of Pfizer Inc. (NYSE:PFE)

Steel Grove Capital Advisors LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 438.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,822 shares of the biopharmaceutical company's stock after purchasing an additional 56,033 shares during the quarter. Steel Grove Capital Advisors LLC's holdings in Pfizer were worth $1,744,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Rialto Wealth Management LLC acquired a new stake in Pfizer during the 4th quarter worth about $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth $27,000. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the fourth quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $30,000. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.13 during trading on Thursday, hitting $23.88. 37,055,113 shares of the stock were exchanged, compared to its average volume of 41,246,625. The company has a market capitalization of $135.74 billion, a price-to-earnings ratio of 17.30, a price-to-earnings-growth ratio of 0.87 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company's fifty day simple moving average is $23.17 and its 200-day simple moving average is $24.92.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.82 earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.20%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.